General Information of Drug (ID: DM4PM1G)

Drug Name
ISIS 13920 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
TTD Drug ID
DM4PM1G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS 2503 DMEMKIS N. A. N. A. Discontinued in Phase 2 [2]
ISIS 6186 DMH7LPO Discovery agent N.A. Investigative [3]
ISIS 2502 DMYTXBS Discovery agent N.A. Investigative [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
H-ras messenger RNA (HRAS mRNA) TT28ZON RASH_HUMAN Not Available [1]

References

1 US patent application no. 7,425,545, Modulation of C-reactive protein expression.
2 A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan;9(1):115-23.
3 US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides.